Finally, compound 3, known as α-Cyano-4-hydroxycinnamic acid (α-CCA), has been recognised for its anti-tyrosinase activity and its impact on aldose reductase, suggesting potential benefits for Alzheimer’s disease [48,49]. Here, AKR1B1 is linked to early-onset autosomal dominant Alzheimer disease.